Cargando…
Number of metastatic organs negatively affects the treatment sequence in patients with EGFR‐TKI failure
BACKGROUND: Several studies have previously demonstrated the survival benefit of both EGFR‐TKI treatment and chemotherapy in patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after fai...
Autores principales: | Mizuno, Takaaki, Horinouchi, Hidehito, Watanabe, Sho, Sato, Jun, Morita, Ryo, Murakami, Shuji, Goto, Yasushi, Kanda, Shintaro, Fujiwara, Yutaka, Yamamoto, Noboru, Ohe, Yuichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113048/ https://www.ncbi.nlm.nih.gov/pubmed/32077630 http://dx.doi.org/10.1111/1759-7714.13360 |
Ejemplares similares
-
Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations
por: Shinno, Yuki, et al.
Publicado: (2018) -
Mixed response to osimertinib and the beneficial effects of additional local therapy
por: Shinno, Yuki, et al.
Publicado: (2019) -
Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
por: Tamura, Nobumasa, et al.
Publicado: (2019) -
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody
por: Murakami, Shuji, et al.
Publicado: (2020) -
Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients
por: Higashiyama, Ryoko Inaba, et al.
Publicado: (2022)